These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 17805032

  • 1. Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone.
    Christoforidis A, Zevgaridou E, Tsatra I, Perifanis V, Vlachaki E, Papassotiriou I, Apostolakou F, Athanassiou-Metaxa M.
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):598-601. PubMed ID: 17805032
    [Abstract] [Full Text] [Related]

  • 2. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P.
    Blood Cells Mol Dis; 2009 Sep; 42(3):247-51. PubMed ID: 19233692
    [Abstract] [Full Text] [Related]

  • 3. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P.
    Blood Cells Mol Dis; 2010 Aug 15; 45(2):136-9. PubMed ID: 20678715
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
    Ricchi P, Ammirabile M, Spasiano A, Costantini S, Cinque P, Di Matola T, Pagano L, Prossomariti L.
    Eur J Haematol; 2010 Jul 15; 85(1):36-42. PubMed ID: 20331740
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined therapy with deferoxamine and deferiprone.
    Kattamis A.
    Ann N Y Acad Sci; 2005 Jul 15; 1054():175-82. PubMed ID: 16339663
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A.
    Hemoglobin; 2008 Jul 15; 32(1-2):29-34. PubMed ID: 18274980
    [Abstract] [Full Text] [Related]

  • 15. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens.
    Christoforidis A, Haritandi A, Tsatra I, Tsitourides I, Karyda S, Athanassiou-Metaxa M.
    Eur J Haematol; 2007 Jan 15; 78(1):52-7. PubMed ID: 17042760
    [Abstract] [Full Text] [Related]

  • 16. Evolution of OGTT in patients with beta-thalassaemia major in relation to chelation therapy.
    Christoforidis A, Perifanis V, Tsatra I, Vlachaki E, Athanassiou-Metaxa M.
    Diabetes Res Clin Pract; 2007 Apr 15; 76(1):6-11. PubMed ID: 16930760
    [Abstract] [Full Text] [Related]

  • 17. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY, Mok AS, Chu WC, Raskalkar DD, Cheuk DK, Chiang AK, Ho MH, Chan GC.
    Hemoglobin; 2009 Apr 15; 33(5):323-31. PubMed ID: 19814678
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH, Chen X, Wu CC, Wu KH, Song TS, Weng TF, Hsieh YW, Peng CT.
    Expert Rev Hematol; 2019 Apr 15; 12(4):265-272. PubMed ID: 30920854
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone.
    Alymara V, Bourantas D, Chaidos A, Bouranta P, Gouva M, Vassou A, Tzouvara E, Bourantas KL.
    Hematol J; 2004 Apr 15; 5(6):475-9. PubMed ID: 15570288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.